A good example is rapamycin, currently being tested for treatment of various vascular malformations associated with hyperactivation of the phosphoinositide 3–kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway [27] and linked to mutations in PIK3CA or PTEN [2]. This evidence concerns the gene PTEN and vascular malformation.